Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

She’s Building Bridges Between People and Place – Meet Karin, the Placemaker Behind the Future of Flemingsberg

Karin Lekberg is paving the way for the Flemingsberg of the future — a place where knowledge and creativity meet. She envisions a vibrant area full of culture, evening and nightlife, and a natural meeting place for both students and creators. But when the goal feels far away, it’s about starting where you are — creating life and activity here and now, and above all, building on the stories that already exist, allowing the place to grow into its future.

Flemingsberg Brought Color to Nordic Life Science Days

Flemingsberg is a place where research and progress never sleep. A place where someone is always working on a solution. During Nordic Life Science Days in Gothenburg, Flemingsberg stood out from afar — with an orange booth that, just like Flemingsberg itself, was full of surprises, experiences, and served as an excellent meeting spot for life science enthusiasts.

OptiCell Solutions enters a research collaboration with Karolinska Institutet

With the goal of supporting academia, healthcare, and industry in developing the cell and gene therapies of the future, OptiCell Solutions established its operations in Flemingsberg last year. The company has now entered into a research collaboration with Karolinska Institutet, marking a significant step in the desired direction.